Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.

Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL

Endocrinology2 Jun 2005Cited by 244 (Europe PMC)

PMID15932924DOI10.1210/en.2005-0473PepBankPUB-15932924

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, exendin‑4 alone decreased food intake by up to 83%.
In plain wordsIn mice, exendin‑4 alone reduced food intake by up to 83%.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake with exendin-4 alone
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intraperitonealAs given in this study (mouse).
Source sentences
Summary
Ex4 and PYY(3-36NH2) alone decreased FI by up to 83 and 26%, respectively (P < 0.05-0.001),
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
Report a problemFND-1593292401

Studies that did not test the peptide alone7

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

02AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In mice, combined exendin‑4 and PYY synergistically reduced food intake further than either peptide alone for up to 8 h.
In plain wordsIn mice, exendin‑4 plus PYY reduced food intake more than either peptide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake with combination
Study
mousen: not reported in source
Male C57BL/6 mice
Comparator
Each peptide alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
whereas a combination of the two peptides (0.06 microg Ex4 plus 3 microg PYY(3-36NH2)) further reduced FI for up to 8 h in a synergistic manner (P < 0.05-0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292402
03AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In mice, exendin‑4 and/or PYY delayed gastric emptying by a maximum of 19% without a separate exendin‑4 estimate.
In plain wordsIn mice, exendin‑4 and/or PYY delayed stomach emptying, without a separate exendin‑4 estimate.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGastric emptying in pooled regimens
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Ex4 and/or PYY(3-36NH2) delayed gastric emptying by a maximum of 19% (P < 0.01-0.001); however, there was no significant effect on locomotor activity nor was there induction of taste aversion.
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292403
04AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Safety outcome
In mice, exendin‑4 and/or PYY had no significant effect on locomotor activity.
In plain wordsIn mice, exendin‑4 and/or PYY did not significantly change movement.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLocomotor activity in pooled regimens
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
Ex4 and/or PYY(3-36NH2) delayed gastric emptying by a maximum of 19% (P < 0.01-0.001); however, there was no significant effect on locomotor activity nor was there induction of taste aversion.
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292404
05AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Safety outcome
In mice, exendin‑4 and/or PYY did not induce taste aversion.
In plain wordsIn mice, exendin‑4 and/or PYY did not cause taste aversion.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTaste aversion in pooled regimens
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Ex4 and/or PYY(3-36NH2) delayed gastric emptying by a maximum of 19% (P < 0.01-0.001); however, there was no significant effect on locomotor activity nor was there induction of taste aversion.
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292405
06AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In mice, capsaicin pretreatment prevented exendin‑4-induced suppression of food intake.
In plain wordsIn mice, capsaicin pretreatment blocked the reduction in food intake induced by exendin‑4.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCapsaicin sensitivity of anorexia
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Capsaicin pretreatment prevented the inhibitory effect of Ex4 on FI (P < 0.05), but had no effect on the anorexigenic actions of PYY(3-36NH2).
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292406
07AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In mice, exendin‑4(9-39) partially abolished exendin‑4-induced anorexia.
In plain wordsIn mice, a GLP-1 receptor blocker partly blocked the reduction in food intake induced by exendin‑4.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGLP-1 receptor antagonist sensitivity
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Similarly, exendin-4(9-39) (a GLP-1 receptor antagonist) partially abolished Ex4-induced anorexia (P < 0.05), but did not affect the satiation produced by PYY(3-36NH2).
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292407
08AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In mice, BIIE0246 did not affect exendin‑4-induced satiety.
In plain wordsIn mice, a Y2 receptor blocker did not change the fullness effect induced by exendin‑4.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeY2 receptor antagonist sensitivity
Study
mousen: not reported in source
Male C57BL/6 mice
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Conversely, BIIE0246 (a Y2 receptor antagonist) completely blocked the anorexigenic effects of PYY(3-36NH2) (P < 0.001), but had no effect on Ex4-induced satiety.
1 context sentence(design, population, supporting numbers)
Summary · context
Male C57BL/6 mice were injected (ip) with exendin-4(1-39) (Ex4, a GLP-1 receptor agonist) and/or PYY(3-36NH2) (0.03-3 microg), and FI was determined for up to 24 h.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1593292408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.